Fondaparinux frente a enoxaparin como profilaxis del tromboembolismo venoso.

Wade WE, Spruill WJ, Leslie RB.
Department of Clinical and Administrative Pharmacy, College of Pharmacy University of Georgia, Athens, Georgia 30602-2354, USA. bwade@mail.rx.uga.edu

Hip fracture patients are at high risk of developing venous thromboembolic events (VTEs) postoperatively. Efficacy and safety data from a clinical trial comparing fondaparinux and enoxaparin as VTE prophylaxis were used to perform a cost assessment of these 2 agents. Incremental cost calculations demonstrate that enoxaparin offers advantages over fondaparinux when dosed for 7 days postoperatively in this patient population. Sensitivity analyses support this finding at the lower extreme; however, fondaparinux provides cost savings at the upper extreme. Cost per death averted and cost per life year gained are similar for these 2 agents in these patients.